MarketCap
Facebook
X
TelegramAnnual report 2022
added 08-16-2022
Global Cord Blood Corporation Balance Sheet 2011-2025 | CO
Annual Balance Sheet Global Cord Blood Corporation
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-6.07 B | -5.47 B | -5 B | -4.25 B | -2.48 B | -2.04 B | -1.56 B | -1.05 B | -692 M | -749 M | -566 M | |
Long Term Debt |
- | 147 K | - | - | - | - | 906 M | 816 M | 778 M | 752 M | - | - |
Long Term Debt Current |
147 K | 1.64 M | 1.72 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 2.53 B | 2.26 B | 1.89 B | 2.51 B | 2.16 B | 1.79 B | 1.41 B | 391 M | 220 M |
Total Current Liabilities |
647 M | 626 M | 571 M | 596 M | 468 M | 1.45 B | 468 M | 420 M | 397 M | 332 M | 197 M | - |
Total Liabilities |
3.65 B | 3.52 B | 3.33 B | 3.13 B | 2.73 B | 3.34 B | 2.97 B | 2.58 B | 2.19 B | 1.74 B | 589 M | 470 M |
Deferred Revenue |
458 M | 449 M | 403 M | 462 M | 366 M | 324 M | 258 M | 220 M | 196 M | 172 M | 106 M | 82.3 M |
Retained Earnings |
2.89 B | 2.39 B | 1.88 B | 1.41 B | 1.12 B | 880 M | 754 M | 663 M | 555 M | 423 M | 311 M | 179 M |
Total Assets |
8.53 B | 7.91 B | 7.22 B | 6.55 B | 5.84 B | 5.18 B | 4.69 B | 4.12 B | 3.63 B | 2.99 B | 1.82 B | 1.56 B |
Cash and Cash Equivalents |
6.66 B | 6.08 B | 5.47 B | 5 B | 4.25 B | 3.51 B | 3.01 B | 2.44 B | 1.88 B | 1.49 B | 794 M | 611 M |
Book Value |
4.88 B | 4.39 B | 3.89 B | 3.42 B | 3.12 B | 1.84 B | 1.71 B | 1.54 B | 1.44 B | 1.24 B | 1.24 B | 1.09 B |
Total Shareholders Equity |
4.88 B | 4.38 B | 3.89 B | 3.42 B | 3.11 B | 1.84 B | 1.71 B | 1.54 B | 1.44 B | 1.24 B | 1.2 B | 1.09 B |
All numbers in CNY currency
Quarterly Balance Sheet Global Cord Blood Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | 50 K | - | 147 K | - | 1.72 M | - | 1.78 M | - | 3.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 755 M | - | 752 M | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | 3.65 B | - | 3.6 B | - | 3.52 B | - | 3.42 B | - | 3.33 B | - | 3.27 B | - | 3.13 B | - | 2.92 B | - | 2.73 B | - | 2.58 B | - | 3.34 B | - | 3.1 B | - | 2.97 B | - | 2.75 B | - | 2.57 B | - | 2.37 B | - | 2.19 B | - | 1.9 B | 1.8 B | 1.74 B | - | 1.22 B | 1.06 B | 589 M | 524 M | 485 M | - | 470 M |
Deferred Revenue |
- | - | - | 458 M | - | 451 M | - | 449 M | - | 421 M | - | 403 M | - | 444 M | - | 462 M | - | 388 M | - | 366 M | - | 375 M | - | 324 M | - | 293 M | - | 258 M | - | 248 M | - | 220 M | - | 208 M | - | 196 M | - | 181 M | 176 M | 172 M | - | 151 M | 130 M | 106 M | 91.3 M | 87.2 M | - | 82.3 M |
Retained Earnings |
- | - | - | 2.89 B | - | 2.65 B | - | 2.39 B | - | 2.14 B | - | 1.88 B | - | 1.64 B | - | 1.41 B | - | 1.25 B | - | 1.12 B | - | 1.02 B | - | 880 M | - | 786 M | - | 754 M | - | 695 M | - | 663 M | - | 612 M | - | 555 M | - | 481 M | 456 M | 423 M | - | 367 M | 342 M | 311 M | 282 M | 242 M | - | 179 M |
Total Assets |
- | - | - | 8.53 B | - | 8.26 B | - | 7.91 B | - | 7.57 B | - | 7.22 B | - | 6.95 B | - | 6.55 B | - | 6.2 B | - | 5.84 B | - | 5.57 B | - | 5.18 B | - | 4.85 B | - | 4.69 B | - | 4.37 B | - | 4.11 B | - | 3.87 B | - | 3.63 B | - | 3.29 B | 3.11 B | 2.99 B | - | 2.42 B | 2.27 B | 1.82 B | 1.67 B | 1.6 B | - | 1.56 B |
Cash and Cash Equivalents |
- | - | - | 6.66 B | - | 6.39 B | - | 6.08 B | - | 5.73 B | - | 5.47 B | - | 5.37 B | - | 5 B | - | 4.61 B | - | 4.25 B | - | 3.93 B | - | 3.51 B | - | 3.14 B | - | 3.01 B | - | 2.67 B | - | 2.44 B | - | 2.16 B | - | 1.88 B | - | 1.67 B | 1.56 B | 1.49 B | - | 1.32 B | 1.15 B | 794 M | 717 M | 636 M | - | 611 M |
Book Value |
- | - | - | 4.88 B | - | 4.65 B | - | 4.39 B | - | 4.15 B | - | 3.89 B | - | 3.68 B | - | 3.42 B | - | 3.28 B | - | 3.12 B | - | 2.98 B | - | 1.84 B | - | 1.75 B | - | 1.71 B | - | 1.62 B | - | 1.54 B | - | 1.49 B | - | 1.44 B | - | 1.39 B | 1.31 B | 1.24 B | - | 1.2 B | 1.21 B | 1.24 B | 1.15 B | 1.11 B | - | 1.09 B |
Total Shareholders Equity |
- | - | - | 4.88 B | - | 4.64 B | 4.53 B | 4.38 B | - | 4.14 B | 4.02 B | 3.88 B | - | 3.67 B | 3.54 B | 3.42 B | - | 3.27 B | 3.15 B | 3.11 B | - | 2.97 B | - | 1.84 B | - | 1.75 B | - | 1.71 B | - | 1.61 B | - | 1.54 B | - | 1.49 B | - | 1.44 B | - | 1.39 B | 1.3 B | 1.24 B | - | 1.16 B | 1.18 B | 1.2 B | 1.12 B | 1.08 B | - | 1.07 B |
All numbers in CNY currency
Balance Sheet is a fundamental financial report of Global Cord Blood Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
$ 19.02 | 0.21 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
$ 20.99 | 1.77 % | $ 226 M |  China |
 |
Co-Diagnostics
CODX
|
$ 0.17 | -3.71 % | $ 4.99 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
$ 39.06 | -0.64 % | $ 1.08 B | USA |
 |
Danaher Corporation
DHR
|
$ 230.1 | -0.25 % | $ 168 B | USA |
 |
DarioHealth Corp.
DRIO
|
$ 10.95 | 2.34 % | $ 311 M | Israel |
 |
BioNano Genomics
BNGO
|
$ 1.52 | 1.23 % | $ 1.93 M | USA |
 |
Exact Sciences Corporation
EXAS
|
$ 101.89 | -0.01 % | $ 18.9 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M |  Britain |
 |
DexCom
DXCM
|
$ 66.73 | -0.5 % | $ 25.8 B | USA |
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
$ 26.31 | -0.7 % | $ 795 M | USA |
 |
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
- | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
$ 18.96 | -0.6 % | $ 1.02 B | USA |
 |
Celcuity
CELC
|
$ 99.66 | -0.26 % | $ 3.93 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.14 | 0.64 % | $ 100 K | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
$ 226.62 | -0.47 % | $ 41.1 B | USA |
 |
Guardant Health
GH
|
$ 102.42 | 1.81 % | $ 12.6 B | USA |
 |
NeoGenomics
NEO
|
$ 11.95 | -2.29 % | $ 1.51 B | USA |
 |
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
$ 6.14 | -0.57 % | $ 556 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 4.5 | -5.46 % | $ 2.42 M | USA |
 |
Neogen Corporation
NEOG
|
$ 7.07 | 0.21 % | $ 1.53 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 27.22 | -0.62 % | $ 20 B |  Niderland |
 |
Personalis
PSNL
|
$ 8.02 | 0.63 % | $ 475 M | USA |
 |
Quidel Corporation
QDEL
|
$ 28.81 | -1.67 % | $ 1.21 B | USA |
 |
National Research Corporation
NRC
|
$ 18.73 | 0.43 % | $ 460 M | USA |
 |
RadNet
RDNT
|
$ 71.37 | -0.17 % | $ 5.21 B | USA |
 |
Illumina
ILMN
|
$ 131.22 | -1.15 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 200.86 | -0.55 % | $ 10.3 B | USA |
 |
Soleno Therapeutics
SLNO
|
$ 45.87 | -0.91 % | $ 1.84 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 174.42 | -0.61 % | $ 19.4 B | USA |
|
Biodesix
BDSX
|
$ 6.78 | 0.86 % | $ 879 M | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
$ 251.89 | -0.47 % | $ 21.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
$ 182.34 | -0.36 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 679.3 | -0.44 % | $ 56 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 67.01 | -0.22 % | $ 4.64 B | USA |